Musk’s $8.5 Billion Tesla Stock Sales Make Math Behind Twitter Deal More Tricky

image

(Bloomberg) — Elon Musk’s sale of more than $8.5 billion of Tesla Inc. shares has made the math behind his $44 billion deal to buy Twitter Inc. a bit more tricky.

To acquire the social-media company, Musk has lined up $13 billion in bank financing, $12.5 billion in margin loans backed by Tesla shares and committed a further $21 billion himself.

Before his most recent share sales, the Tesla co-founder had about $3 billion in cash and investments to cover that $21 billion commitment, according to Bloomberg calculations. The recent disposals bring that total to about $11.5 billion.

But as a result of the trades, Musk has fewer shares to cover his margin loan, which has an initial loan-to-value ratio of 20%. That means he’ll need to post Tesla shares worth $62.5 billion when it’s funded.

He now has 163 million shares remaining worth about $146 billion, though more than half are already pledged to secure existing personal debt, according to Tesla’s most recent proxy statement. If the electric carmaker’s share price drops under $837 — or about 7% below where it is currently — he won’t own enough stock to secure the loan. The shares traded as low as $821.70 as recently as Thursday.

The calculations assume he can’t post shares related to Tesla options because the collateral needs to be “free of any lock-up or selling restrictions,” according to a filing. The options he owns convert to shares that can’t be sold for five years.

Musk has said that he’s trying to convince new or or existing equity investors to join him in the Twitter deal. If successful, that reduces the amount he needs to contribute.

Musk said in a tweet Thursday that he has “no further Tesla sales planned after today.” But he still has time to submit more regulatory filings if additional sales took place that day.

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More